Pentobarbital will decrease the level or effect of roflumilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness pentobarbital will decrease the level or effect of irinotecan liposomal ort affecting hep... https://chancetuunl.glifeblog.com/29532334/vad-betyder-det